Pfizer Corporation

Merck Patent Gmbh

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Viiv Healthcare UK Limited

Pharmacia & Upjohn Company

Epizyme, Inc.

Evotec International Gmbh

Exscientia Ltd.

Pfizer Products Inc.

Ziarco Pharma Ltd.

Ziarco Inc.

Andrew Simon Bell

David Graham Brown

Ian Roger Marsh

Michael John Palmer

Peter Thomas Stephenson

David Nathan Abraham Fox

Jeremy Besnard

Yoshinori Aihara

Andrew Ian Morrell

Carol Ann Winslow

Alan Daniel Brown

David James Rawson

Hidefumi Yoshinaga

Nigel Alan Swain

Robert Ian Storer

Russell Andrew Lewthwaite

Yohei Ikuma

Nicholas Kenneth Terrett

Satoshi Adachi

Junya Ikeda

Harunobu Mitsunuma

Kenneth Richardson

Kevin Neil Dack

Karl Richard Gibson

Dafydd Rhys Owen

Peter J Whittle

David Simon Millan

Florian Michel Wakenhut

Marcel John De Groot

Manuel Perez Pacheco

Nunzio Sciammetta

John Mark Francis Gardner

Iain Brian Gardner

David Cameron Pryde

John Nicholas Freskos

Richard Chesworth

Kevin Wayne Kuntz

David Louis Brown

Thomas Edward Rogers

Michael John Munchhof

Yvette M Fobian

Michael B Tollefson

Ernest S Hamanaka

Lorna Helen Mitchell

Paul Anthony Stupple

David Hepworth

Christopher Ronald Smith

Robert Owen Hughes

Michael J Fray

Matthew Duncan Selby

Charlotte Alice Louise Lane

Brent V Mischke

Richard Louis Elliott

David Ellis

Charles Eric Mowbray

E Jon Jacobsen

Todd M Maddux

Megan Alene Cloonan Foley

Cheryl M Hayward

Duncan Robert Armour

John K Walker

John M Molyneaux

Douglas Alan Scully

David Nathan Fox

James Edward John Mills

Yuki Fujii

Christopher Phillips

Blanda Luzia Stammen

Joseph B Moon

Paul John Edwards

Mark Llewellyn Lewis

Alan Patrick Marchington

Manuel Perez-Pacheco

Stephanie Versluys

Adrian Michael Schreyer

Steven Matthieu Gaulier

Masayuki Sakuma

Steven E Heasley

D Joseph Rogier, Jr

Hwang Fun Lu

Charlotte Alice Lane

David Howard Williams

Jeffrey Wayne Corbett

Eric Jon Jacobsen

Yvette Marlene Fobian

Donald Joseph Rogier

Todd Michael Maddux

Joseph Blair Moon

Brent Virgil Mischke

The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

Substituted pyrazoles showing serotonin 5-HT receptor activity

The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors ofgrowth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

Compounds for use in the treatment of fascioliasis

The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein Ris an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and Ris an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).

Pyrazolopyrimidine compounds as adenosine receptor antagonists

Substituted lactams showing serotonin 5-HT receptor activity

The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HTreceptors and serotonin 5-HTreceptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; Rthrough R, Rthrough R, and Rthrough Rare a hydrogen atom and the like; Ris alkyl and the like; and Q is a specific bicyclic group.)

Aliphatic acid amide derivative

The present invention relates to compounds of formula (1a), formula (1b), formula (1c) or formula (1d): or, or a pharmaceutically acceptable salt thereof, which have activity as inhibitors ofgrowth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as

Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis

Condensed lactam derivative

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted piperidine compounds

The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.

Inhibitors of HIV replication

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Chemical compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar, X, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes.  These compounds are inhibitors of Nav1.7.

Sulfonamide derivatives as Nav 1.7 inhibitors

This invention relates to compounds of formula (I) 

Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors

A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R, R, R, R, R, and Rare as defined above.

Pyrimidine derivatives

Growing community of inventors

Sandwich, United Kingdom

Andrew Simon Bell